Grupo de Investigación Oncología Traslacional- Hospital Universitario Lucus Augusti (GIOT-HULA)

Objectives

Our research group focuses on collaborative work between clinicians and researchers to deepen our understanding of cancer, with the aim of enabling more effective and personalized treatments in the future.

Research lines

•Investigation of the molecular basis of various types of cancer, primarily bladder, lung, and breast cancer.
•Development of new cancer diagnostic methods through non-invasive techniques (using blood serum/plasma and urine samples).
•Study of the role of the gut microbiome as a biomarker for the development and prognosis of breast cancer.
•Identification of clinical, radiological, cellular, and molecular markers that define response patterns to treatments used in clinical practice.
•Use of proteomic and genomic techniques for the discovery of early diagnostic and predictive markers of progression and treatment response in tumor diseases.

Determinación de la concentración de inmunomarcadores (citoquinas, quimioquinas y factores de crecimiento) presentes en cada una de las muestras (sangre y orina) empleando los kits Bio-Plex Pro™ Human Chemokine IFN-γ Set y Bio-Plex Pro™ Human Cytokine 8-plex Assay (Bio-Rad) del ensayo clínico “Efficacy of Atezolizumab concurrent with radiotherapy in patients with muscle-invasive bladder cancer (ATEZOBLADDERPRESERVE)” ”
Entidad financiadora: Grupo Español de Oncología Genitourinaria (SOGUG) (promotor) con la colaboración de Roche. (Código: SOGUG-2017-A-IEC (VEJ)-4)
Financiación obtenida: 92.284,50 Euros
Duración: 2020-2027

Estudio del microbioma Intestinal en pacientes de cáncer de mama luminal
Entidad financiadora: Fundación Sociedad Oncología de Galicia (FSOG) Oncología de Precisión
Financiación obtenida: 20.000,00 Euros
Duración: 2024-2026
Investigador principal: Ignacio Fernández Sobrado

Fernández Calvo O, Muñoz Iglesias J, Abou Jokh Casas E, Molina-Díaz A, Anido Herranz U, Casas Nebra J, García-Bernardo L, Martínez-Breijo S, Lázaro-Quintela M, Muñiz-García G, Vázquez-Estevez S. Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of 177Lu-PSMA-617 radioligand-therapy in prostate cancer. Clin Transl Oncol. 2024 Sep 12. doi: 10.1007/s12094-024-03662-7. DOI: 10.1007/s12094-024-03662-7

Provencio M, Robado de Lope L, Serna-Blasco R, Nadal E, Diz Tain P, Massuti B, González-Larriba JL, Insa A, Sánchez-Hernández A, Casal-Rubio J, García-Campelo R, Sequero López S, Rogado J, Martínez-Martí A, Bosch-Barrera J, Bernabé R, Vázquez Estévez S, Ponce S, de Castro J, Coves Sarto J, Reguart N, Dómine M, Aguilar A, Majem M, Estival A, Peña Cabia S, López Martín A, Sala González MÁ, Cobo M, Camps C, Barneto I, Calvo V, Collazo-Lorduy A, Cruz-Bermúdez A, Romero A. BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. Lung Cancer. 2024 Aug;194:107865. DOI:10.1016/j.lungcan.2024.107865

Motzer RJ, Russo P, Grünwald V, Tomita Y, Zurawski B, Parikh O, Buti S, Barthélémy P, Goh JC, Ye D, Lingua A, Lattouf JB, Albigès L, George S, Shuch B, Sosman J, Staehler M, Vázquez Estévez S, Simsek B, Spiridigliozzi J, Chudnovsky A, Bex A. Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. Lancet. 2023 Mar 11;401(10379):821-832. DOI: 10.1016/S0140-6736(22)02574-0

Fernandez-Perez MP, Perez-Navarro E, Alonso-Gordoa T, Conteduca V, Font A, Vázquez-Estévez S, González-Del-Alba A, Wetterskog D, Antonarakis ES, Mellado B, Fernandez-Calvo O, Méndez-Vidal MJ, Climent MA, Duran I, Gallardo E, Rodriguez Sanchez A, Santander C, Sáez MI, Puente J, Tudela J, Martínez A, López-Andreo MJ, Padilla J, Lozano R, Hervas D, Luo J, de Giorgi U, Castellano D, Attard G, Grande E, Gonzalez-Billalabeitia E. A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide. Prostate. 2023 Mar;83(4):376-384. DOI: 10.1002/pros.24469

Bellmunt J, Valderrama BP, Puente J, Grande E, Bolós MV, Lainez N, Vázquez S, Maroto P, Climent MÁ, Garcia Del Muro X, Arranz JÁ, Durán I. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. Crit Rev Oncol Hematol. 2022 Jun;174:103683. DOI: 10.1016/j.critrevonc.2022.103683

Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, Aguado C, Franco F, Gutierrez V, López Vivanco G, Guirado M, Benítez G, Estival A, Calvo V, Jiménez B, Arasanz H, Coves J, Majem M, Massutí B, Vázquez S, Juan-Vidal O, Collazo-Lorduy A, Gozálvez CL, Del Barco E, Rosero A, Bosch-Barrerra J, Moreno MA, Mielgo-Rubio X, Villa JC, López-Martin A, Córdoba JF, de Asís Aparisi F, Zafra M, Mosquera J, Pérez Altozano J, Nadal E, Catot S, Balsalobre J, de Portugal T, Martín P, Cuesta de Juan S, Cobo M. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study. Transl Lung Cancer Res. 2022 Jan;11(1):53-63. DOI: 10.21037/tlcr-21-504